CMHX008 protects HFD induced obesity and insulin resistance.

<p>C57BL/6 mice were fed with HFD or LFD for 16 weeks. Then HFD fed C57BL/6 mice were treated with CMHX008 (3 and 10 mg/kg, HFD-C3 and HFD-C10), rosiglitazone (3 mg/kg, HFD-Rosi) or vehicle (HFD-Veh or LFD-Veh) only. After 4 weeks treatment, intra-peritoneal glucose tolerance tests (iGTTs) were performed (B) and area under curve (AUC) of iGTTs was calculated (B, inserted Figure). Changes in body weight (A), fasting insulin levels (C), morphology of adipocytes (D), quantified adipocyte size (E), mass of epididymal adipose tissues (WAT, F) and aP2 mRNA levels (G) were examined. Data are the means ± S.E.M., n = 6–8; ^#<i>P<</i>0.05 <i>vs</i> LFD-Veh and *<i>P<</i>0.05 <i>vs</i> HFD-Veh.